Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a probiotic cocktail delay Parkinson's? new trial launches

NCT ID NCT07619560

Disease control Sponsor: Taipei Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a daily supplement containing a specific probiotic, tryptophan, and branched-chain amino acids can slow the progression of early-stage Parkinson's disease. Researchers will recruit 120 participants and randomly assign them to receive either the supplement or a placebo for 12 weeks. The goal is to see if the cocktail improves motor, cognitive, and non-motor symptoms, and to build a model that predicts individual disease progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Probiotic Y7, tryptophan, and branched-chain amino acids (valine, leucine, isoleucine)
What this could lead to
If it works, this could point toward a simple dietary supplement that slows Parkinson's progression and improves motor and cognitive function.
What could go wrong
This is an early-stage trial with only 120 participants over 12 weeks. The supplement may show no benefit, and results may not apply to all Parkinson's patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subject Inclusion Criteria: 1. Age between 30-85 years old. 2. Diagnosed with early-stage Parkinson's disease (Hoehn and Yahr scale stage 1-3). 3. Brain MRI confirms striatal degeneration in the basal ganglia region, with no history of stroke. 4. Responds to Parkinson's disease-related medications (e.g., Levodopa). 5. Free of any major or acute illnesses. 6. Able to comply with the 12 weeks intervention and required assessments for the study. Exclusion Criteria: 1. Unable to complete interviews or has mobility issues. 2. Presence of major or acute illness before or during the study. 3. Co-existing intestinal co-infections, such as CDI, E. coli, Salmonella, Shigella, Campylobacter, plague, or cytomegalovirus. 4. Allergic to the intervention product. 5. Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gut microbiota are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gut microbiota Parkinson disease (PD) Probiotic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Taipei Medical University Hospital

    RECRUITING

    Taipei, 110, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.